Article

Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma

2025-06-07

Abstract excerpt

RET gene rearrangements yield oncogenic fusion proteins that drive a subset of lung adenocarcinomas (LUAD). The tyrosine kinase inhibitors (TKIs) selpercatinib and pralsetinib are approved therapies for RET+ lung cancers and have markedly improved clinical outcomes in these patients, but acquired resistance remains a hurdle to their durable management. Using a recently developed murine model of RET+ lung cancer dr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fcedad7b-db83-55cc-bfce-b381825bea59
DOI: 10.1101/2025.06.04.657911

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinomaDOI 10.1101/2025.06.04.657911Read

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.Semantic proximity Read

Treatment of non–small cell lung cancer with RET rearrangementsSemantic proximity Read

Targeting RET alterations in non-small cell lung cancer.Semantic proximity Read

Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.Semantic proximity Read

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with CrizotinibSemantic proximity Read

Therapeutic strategies in RET gene rearranged non-small cell lung cancerSemantic proximity Read

Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung CancerSemantic proximity Read

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.Semantic proximity Read

Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cellsSemantic proximity Read

Another Slice of the Pie Uncovered: RIT1M90I Is an Actionable Driver in Non-Small Cell Lung Cancer.Semantic proximity Read

BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.Semantic proximity Read

An early look at selective RET inhibitor resistance: new challenges and opportunities.Semantic proximity Read